# Protara Therapeutics (TARA) — Analyst Forecast

TARA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/tara/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 8 | 0 | 0 | 8 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| May 20, 2026 | Oppenheimer | Maintained | Outperform | $28.00 |
| May 14, 2026 | JP Morgan | Maintained | Overweight | $26.00 |
| Apr 29, 2026 | HC Wainwright & Co. | Maintained | Buy | $27.00 |
| Mar 4, 2026 | JP Morgan | Initiated Coverage | Overweight | $27.00 |
| Feb 10, 2026 | HC Wainwright & Co. | Maintained | Buy | $23.00 |
| Jan 7, 2026 | Piper Sandler | Initiated Coverage | Overweight | $24.00 |
| Dec 3, 2025 | HC Wainwright & Co. | Maintained | Buy | $23.00 |
| Nov 19, 2025 | HC Wainwright & Co. | Maintained | Buy | $23.00 |
| May 22, 2025 | Jones Trading | Initiated Coverage | Buy | $21.00 |
| Apr 28, 2025 | HC Wainwright & Co. | Maintained | Buy | $23.00 |
| Apr 16, 2025 | Scotiabank | Initiated Coverage | Sector Outperform | $12.00 |
| Mar 14, 2025 | Cantor Fitzgerald | Initiated Coverage | Overweight | — |
| Mar 11, 2025 | LifeSci Capital | Initiated Coverage | Outperform | $22.00 |
| Mar 6, 2025 | HC Wainwright & Co. | Maintained | Buy | $23.00 |
| Dec 6, 2024 | HC Wainwright & Co. | Maintained | Buy | $23.00 |
| Dec 6, 2024 | Guggenheim | Maintained | Buy | $20.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Maintained | Buy | $23.00 |
| Aug 12, 2024 | Oppenheimer | Maintained | Outperform | $25.00 |
| Aug 8, 2024 | HC Wainwright & Co. | Maintained | Buy | $23.00 |
| May 6, 2024 | HC Wainwright & Co. | Maintained | Buy | $23.00 |

## Frequently Asked Questions

### Is TARA a buy, sell, or hold?

Analysts covering Protara Therapeutics currently average a Buy rating: 8 buy, 0 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on TARA?

On May 20, 2026, Oppenheimer maintained Protara Therapeutics at Outperform with a price target of $28.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).